Core Viewpoint - Bernstein has raised Eli Lilly's price target from $1,100 to $1,300, indicating an 18% increase from the previous target and a potential upside of 21% to 22% from the current stock price [1][2]. Group 1: Analyst Insights - Analyst Courtney Breen believes that Wall Street has not fully accounted for the potential of Eli Lilly's upcoming GLP-1 catalysts, suggesting that the company's growth story is far from over [3]. - Breen anticipates that 2026 will be a pivotal year for Eli Lilly, marking a transition into a "beat-and-raise" momentum for the company [3]. - The upcoming launch of orforglipron, along with favorable White House policies and the evolution of tirzepatide into a multi-indication platform, contributes to Breen's optimistic outlook [4][5]. Group 2: Financial Projections - Breen's financial model indicates that consensus estimates for Eli Lilly's sales volumes are overly conservative, particularly regarding Medicare, Medicaid, and commercial demand [10]. - The breakthrough year is projected to be 2026, with orforglipron expected to generate sales of $1.8 billion, significantly higher than the Street's estimate of $550 million [11][12]. - Breen's projections are based on U.S.-only assumptions, estimating nearly 80,000 weekly prescriptions in the oral obesity market [12]. Group 3: Analyst Performance - Breen has a notable 94% success rate, with 32 out of 34 stock calls resulting in profits, and her recommendations yield an average return of +21.5% per rating [6][7].